• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet.

作者信息

Otoul Christian, Watanabe Shikiko, McCabe Suzanne, Stockis Armel

机构信息

UCB Pharma, Braine l'Alleud, Belgium.

出版信息

Clin Pharmacol Drug Dev. 2017 May;6(3):313-317. doi: 10.1002/cpdd.275. Epub 2016 Jun 28.

DOI:10.1002/cpdd.275
PMID:27274002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6093258/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/990a/6093258/155a55cbd066/CPDD-6-313-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/990a/6093258/155a55cbd066/CPDD-6-313-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/990a/6093258/155a55cbd066/CPDD-6-313-g001.jpg

相似文献

1
Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet.10毫克/毫升布瓦西坦口服溶液与50毫克薄膜包衣片的相对生物利用度和生物等效性
Clin Pharmacol Drug Dev. 2017 May;6(3):313-317. doi: 10.1002/cpdd.275. Epub 2016 Jun 28.
2
Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus.10毫克、50毫克、75毫克和100毫克布瓦西坦片剂与100毫克静脉推注剂的生物利用度和生物等效性比较
Epilepsia. 2016 Aug;57(8):1288-93. doi: 10.1111/epi.13433. Epub 2016 Jun 26.
3
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.一项单剂量、三周期、六序列交叉研究，比较了空腹条件下健康墨西哥志愿者中镁丙戊酸盐溶液、混悬液和肠溶片剂的生物利用度。
Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.
4
Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets.左乙拉西坦：10%口服溶液（750毫克）与750毫克片剂的相对生物利用度和生物等效性
J Clin Pharmacol. 2003 Dec;43(12):1370-6. doi: 10.1177/0091270003258173.
5
Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects.三种鲁非酰胺口服混悬剂与市售 400 毫克片剂制剂的生物利用度比较：一项在健康受试者中进行的随机、序列、开放标签、四周期、四序列交叉研究的结果。
Clin Ther. 2011 Jan;33(1):146-57. doi: 10.1016/j.clinthera.2011.01.016.
6
Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.布瓦西坦用于治疗局灶性癫痫、特发性全身性癫痫及癫痫持续状态。
Expert Rev Clin Pharmacol. 2016;9(5):637-45. doi: 10.1586/17512433.2016.1156529. Epub 2016 Mar 7.
7
A Pharmacokinetic Study Comparing Eslicarbazepine Acetate Administered Orally as a Crushed or Intact Tablet in Healthy Volunteers.一项比较健康志愿者口服碾碎或完整片剂的依佐加滨醋酸盐的药代动力学研究。
Clin Pharmacol Drug Dev. 2016 Jul;5(4):278-84. doi: 10.1002/cpdd.242. Epub 2016 Feb 8.
8
Brivaracetam disposition in renal impairment.布瓦西坦在肾功能损害中的药物处置。
J Clin Pharmacol. 2012 Dec;52(12):1927-33. doi: 10.1177/0091270011431457. Epub 2012 Jan 10.
9
A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults.拉替拉韦在健康成人中成人剂型与儿童剂型的药代动力学比较。
Antivir Ther. 2014;19(6):619-24. doi: 10.3851/IMP2765. Epub 2014 Mar 7.
10
Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment.片剂和糖浆剂拉科酰胺在血浆、唾液和尿液中的耐受性、药代动力学和生物等效性：唾液作为中央室药代动力学的替代物。
Epilepsia. 2013 Jan;54(1):81-8. doi: 10.1111/j.1528-1167.2012.03725.x. Epub 2012 Nov 13.

引用本文的文献

1
Brivaracetam: Pharmacology, Clinical Efficacy, and Safety in Epilepsy.布立伏西坦：癫痫的药理学、临床疗效及安全性
J Epilepsy Res. 2025 Jun 10;15(1):42-55. doi: 10.14581/jer.25005. eCollection 2025 Jun.
2
Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.布瓦西坦的综述：在癫痫患者治疗中的临床前特征和临床获益。
Adv Ther. 2024 Jul;41(7):2682-2699. doi: 10.1007/s12325-024-02876-z. Epub 2024 May 29.
3
Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial.

本文引用的文献

1
Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.利福平对人受试者中布立西坦处置的影响：对布立西坦水解的进一步认识。
Drug Metab Dispos. 2016 Jun;44(6):792-9. doi: 10.1124/dmd.115.069161. Epub 2016 Mar 21.
2
A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.一项随机、双盲、安慰剂对照、多中心、平行组研究，旨在评估辅助使用布瓦西坦对成人部分性发作控制不佳患者的疗效和安全性。
Epilepsia. 2015 Dec;56(12):1890-8. doi: 10.1111/epi.13212. Epub 2015 Oct 16.
3
静脉注射布瓦西坦在癫痫儿科患者中的药代动力学、安全性和耐受性：一项开放标签试验。
Epilepsia. 2022 Apr;63(4):855-864. doi: 10.1111/epi.17187. Epub 2022 Feb 23.
4
Brivaracetam in the treatment of epilepsy: a review of clinical trial data.布瓦西坦治疗癫痫：临床试验数据综述
Neuropsychiatr Dis Treat. 2019 Sep 9;15:2587-2600. doi: 10.2147/NDT.S143548. eCollection 2019.
5
Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial.在患有癫痫的儿科患者 < 16 岁中添加布瓦西坦的安全性和耐受性：一项开放标签试验。
Paediatr Drugs. 2019 Aug;21(4):291-301. doi: 10.1007/s40272-019-00332-y.
6
A review of the pharmacology and clinical efficacy of brivaracetam.布立西坦的药理学与临床疗效综述。
Clin Pharmacol. 2018 Jan 19;10:1-22. doi: 10.2147/CPAA.S114072. eCollection 2018.
7
Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.1个月至16岁癫痫患儿中布立西坦的群体药代动力学
Eur J Clin Pharmacol. 2017 Jun;73(6):727-733. doi: 10.1007/s00228-017-2230-6. Epub 2017 Mar 9.
Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.
健康日本受试者中布立西坦单次及多次递增口服剂量研究：CYP2C19基因分型的影响
Drug Metab Pharmacokinet. 2014;29(5):394-9. doi: 10.2133/dmpk.dmpk-14-rg-010. Epub 2014 Apr 8.
4
Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.布瓦西坦作为成人部分性癫痫未控制患者的附加治疗：一项 III 期随机、双盲、安慰剂对照试验。
Epilepsia. 2014 Jan;55(1):57-66. doi: 10.1111/epi.12433. Epub 2013 Nov 8.
5
Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.伴用布瓦西坦治疗成人局灶性癫痫发作控制不佳：一项双盲、随机、安慰剂对照试验的结果。
Epilepsia. 2014 Jan;55(1):47-56. doi: 10.1111/epi.12432. Epub 2013 Oct 28.
6
Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.辅助性溴维奈克拉治疗未控制的局灶性和全面性癫痫发作：一项 III 期、双盲、随机、安慰剂对照、剂量灵活的试验结果。
Epilepsia. 2014 Jan;55(1):38-46. doi: 10.1111/epi.12391. Epub 2013 Oct 3.
7
Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.在未得到控制的部分性发作癫痫成人中添加布瓦西坦的疗效和耐受性：一项 IIb 期、随机、对照试验。
Epilepsia. 2013 Jan;54(1):89-97. doi: 10.1111/j.1528-1167.2012.03598.x. Epub 2012 Jul 19.
8
Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.布瓦西坦在大鼠、小鼠和人脑中的结合特性：一种选择性、高亲和力 SV2A 配体与抗惊厥特性的关系。
Eur J Pharmacol. 2011 Aug 16;664(1-3):36-44. doi: 10.1016/j.ejphar.2011.04.064. Epub 2011 May 8.
9
Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.添加布瓦西坦辅助治疗耐药性部分发作性癫痫：一项随机对照试验。
Neurology. 2010 Aug 10;75(6):519-25. doi: 10.1212/WNL.0b013e3181ec7f7f. Epub 2010 Jun 30.
10
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.健康男性多次递增口服剂量后布立西坦的药代动力学、中枢神经系统药效学及不良事件情况
Br J Clin Pharmacol. 2008 Jul;66(1):71-5. doi: 10.1111/j.1365-2125.2008.03158.x. Epub 2008 Mar 13.